Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CAP-IT Clear all

Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
Interventions: NHS7108, Zenpep®; Drug
Lead sponsor: Aimmune Nestlé Health Science US R&D, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Memantine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 3
States / cities: Cleveland, Ohio • Nashville, Tennessee • Houston, Texas

Conditions: Endothelial Dysfunction
Interventions: atrasentan; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Menopause, Menopause Related Conditions, Perimenopausal Disorder
Interventions: Semaine Menopause Supplement; Dietary Supplement
Lead sponsor: Semaine Health; Industry
Eligibility: 40 Years to 57 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Coccidioidomycosis
Interventions: Fluconazole, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 9
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 3 more

Conditions: Malaria
Interventions: Chloroquine (CQ), Pyrimethamine (PYR), Sanaria PfSPZ Challenge (NF54); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms
Interventions: Niraparib, Pembrolizumab, TSR-042 (Dostarlimab); Drug · Biological
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 16
States / cities: Whittier, Alaska • Port Saint Lucie, Florida • Atlanta, Georgia + 13 more

Conditions: Solid Tumors, Hematologic Malignancies
Interventions: Pembrolizumab, Standard of Care (SOC), Lenvatinib, Olaparib, MK-4280, MK-4280A, Pembrolizumab (+) Berahyaluronidase alfa; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2043
U.S. locations: 65
States / cities: Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more

Conditions: Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, Chronic Lymphocytic Leukemia
Interventions: Omega 3 Fatty Acid; Dietary Supplement
Lead sponsor: Marshall University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Huntington, West Virginia

Conditions: Differentiated Thyroid Cancer
Interventions: Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Timeline: Ends 2015
U.S. locations: 13
States / cities: La Jolla, California • Stanford, California • Torrance, California + 10 more

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy
Interventions: Flaxseed Lignans; Dietary Supplement
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 20 Years to 45 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lung Transplant
Interventions: Extended-Release Tacrolimus, Immediate-Release Tacrolimus; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Depression
Interventions: Citalopram, Methylphenidate (MPH), Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 60 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteers
Interventions: GCC-4401C, Rivaroxaban, Placebo; Drug
Lead sponsor: Green Cross Corporation; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Early Phase Clinical Unit _Los Angeles, California

Conditions: Advanced Cancers, Hematologic Disorder, Solid Tumors
Interventions: Dexamethasone, Placebo, Questionnaires, Spirometer, Phone Calls; Drug · Behavioral · Device + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Amyotrophic Lateral Sclerosis ALS
Interventions: Astaxanthin, Protandim, Melatonin, MitoQ; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Surgical Recovery
Interventions: CocoaVia®, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Neoplasm, Skull Base Neoplasm
Interventions: 5-Aminolevulinic acid Hydrochloride; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: New York, New York

Conditions: Primary Sclerosing Cholangitis, Post- Orthotopic Liver Transplantation
Interventions: Vancomycin; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Neurofibromatosis 1, Plexiform Neurofibroma
Interventions: Cabozantinib Oral Tablet, Selumetinib Oral Capsule; Drug
Lead sponsor: Girish Dhall, MD; Other
Eligibility: 16 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 5 more

Conditions: Colorectal Cancer
Interventions: Vitamin D3 (cholecalciferol), Placebo; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 50 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Hypertension
Interventions: Bardoxolone methyl; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 46
States / cities: Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 32 more

Conditions: TBI
Interventions: Omega 3 fatty acid, Safflower seed oil; Drug · Dietary Supplement
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

Correlation of Endothelial Function and Early Coronary Artery Disease in Humans

An Exploratory Investigation of Dietary Supplementation and the Effect on Common Symptoms of Perimenopause and Menopause

Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)

Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

FlaxFx, A Research Study of the Effects of Flaxseed Lignans on Colon Health

Envarsus XR in Lung Transplant

Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

Dexamethasone Dyspnea Study

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

Cocoa Flavanols for Modulating Immune Response and Accelerating Recovery

The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial

Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients

Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas

Efficacy of Vitamin D in Colorectal Cancer Chemoprevention

Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury